On May 23, 2023, financial research firm Stephens & Co. reiterated their coverage of Pennant Group (NASDAQ:PNTG) with an Equal-Weight recommendation, according to Fintel.
Analysts predict a 21.62% increase in the average one-year price target for Pennant Group, suggesting a price target of $15.30. This projection ranges from a low of $14.14 to a high of $16.80.
Pennant Group is expected to generate a projected annual revenue of $506MM, indicating an increase of 4.11%. The projected annual non-GAAP EPS is 0.75.
The put/call ratio of PNTG is 0.12, indicating a bullish outlook, based on data obtained from the 363 funds and institutions that report positions in Pennant Group. The average portfolio weight of all funds dedicated to PNTG is 0.05%, reflecting an 11.11% increase. Total shares owned by institutions decreased in the last three months by 0.53% to 26,889K shares.
Regarding shareholders, T. Rowe Price Investment Management increased its portfolio allocation in PNTG by 22.76% over the last quarter, holding 4,152K shares representing 13.96% ownership of the company, while iShares Core S&P Small-Cap ETF holds 2,117K shares representing 7.12% ownership of the company. Riverbridge Partners owns 1,338K shares representing 4.50% ownership of the company, increasing its portfolio allocation in PNTG by 118,294.76% over the last quarter. Crewe Advisors owns 1,118K shares representing 3.76% ownership of the company, with no change in the last quarter.
The Pennant Group, Inc. operates healthcare services through 80 home health and hospice agencies and 54 senior living communities in 13 US states, each operated by a separate subsidiary. The company’s consolidated assets and activities are not meant to imply direct operating assets, employees, or revenue.
Key filings for this company:
This story originally appeared on Fintel.
The opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
